ADVAXIS, INC. (NASDAQ:ADXS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
The 2017 annual meeting of stockholders of Advaxis was held on
April 5, 2017. The following matters were voted on by the
stockholders: the election of directors, the approval of an
amendment to Advaxis 2015 Incentive Plan to authorize an
additional 1,500,000 shares thereunder and to include a provision
for pre-defined annual increases in the number of shares
available for issuance, the ratification of 2015 stock option
grants under Advaxis 2015 Incentive Plan to certain directors and
officers, and the ratification of the appointment of Marcum LLP
as Advaxis independent registered public accounting firm for the
fiscal year ending October 31, 2017. At the meeting, Dr. David
Sidransky, Dr. James P. Patton, Daniel J. OConnor, Roni A. Appel,
Richard J. Berman, Dr. Samir N. Khleif, Dr. Thomas J. McKearn,
and Thomas J. Ridge were re-elected to the Board.
Proposal 1
The vote with respect to each nominee is set forth below:
| Nominee | Total Votes For | Total Votes Withheld | Broker Non-Votes | |||||||||
| Dr. David Sidransky | 12,324,390 | 6,540,383 | 14,532,686 | |||||||||
| Dr. James P. Patton |
12,589,076 |
6,275,697 | 14,532,686 | |||||||||
| Daniel J. OConnor | 18,263,858 | 600,915 | 14,532,686 | |||||||||
| Roni A. Appel |
18,358,386 |
506,387 | 14,532,686 | |||||||||
| Richard J. Berman |
18,339,699 |
525,074 | 14,532,686 | |||||||||
| Dr. Samir Khleif |
12,761,138 |
6,103,635 | 14,532,686 | |||||||||
| Dr. Thomas J. McKearn |
12,709,321 |
6,155,452 | 14,532,686 | |||||||||
| Thomas J. Ridge |
18,378,020 |
486,753 | 14,532,686 | |||||||||
Proposal 2
The vote with respect to the approval of an amendment to Advaxis
2015 Incentive Plan is set forth below:
| Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 10,328,658 | 8,407,892 | 128,223 | 14,532,686 | |||||||||||
Proposal 3
The vote with respect to the ratification of 2015 stock option
grants under Advaxis 2015 Incentive Plan is set forth below:
| Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 10,644,448 | 8,045,834 | 174,491 | 14,532,686 | |||||||||||
Proposal 4
The vote with respect to the ratification of the appointment of
Marcum LLP as Advaxis independent registered public accounting
firm for the fiscal year ending October 31, 2017, is set forth
below:
| Total Votes For | Total Votes Against | Abstentions | ||||||||
| 32,496,795 | 636,064 | 264,600 | ||||||||
About ADVAXIS, INC. (NASDAQ:ADXS)
Advaxis, Inc. is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company’s immunotherapy candidates include Axalimogene filolisbac, ADXS-PSA and ADXS-HER2. Axalimogene filolisbac (ADXS-HPV) is a lead Lm-LLO immunotherapy product candidate for the treatment of human papilloma virus (HPV) associated cancers. ADXS-PSA is an Lm-LLO immunotherapy product candidate designed to target the Prostate Specific Antigen (PSA) associated with prostate cancer. ADXS-HER2 is an Lm-LLO immunotherapy product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric and other cancers. ADVAXIS, INC. (NASDAQ:ADXS) Recent Trading Information
ADVAXIS, INC. (NASDAQ:ADXS) closed its last trading session up +0.06 at 7.84 with 420,735 shares trading hands.